Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
2019 · PharmacoEconomics - Open · 41 citations
https://doi.org/10.1007/s41669-019-00178-7
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
27
Papers
1.3K
Citations
12
h-index
13
i10-index
Praveen Dhankhar is an academic researcher. The author has contributed to research in topics: Influenza Virus Research Studies & Vaccine Coverage and Hesitancy & COVID-19 epidemiological studies. The author has an h-index of 12, co-authored 23 publications.
https://doi.org/10.1007/s41669-019-00178-7
https://doi.org/10.1186/1471-2458-10-278
https://doi.org/10.1007/s12325-023-02484-3
Click to start Chat